Related Experiment Video

Updated: Feb 21, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K

The effect of a hepatitis pay-for-performance program on outcomes of patients undergoing antiviral therapy

Tsung-Tai Chen1, Ya-Seng Arthur Hsueh2, Chun-Hsiung Ko1

  • 1Department of Public Health, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.

European Journal of Public Health
|October 12, 2017
PubMed

Insights

A participatory pay-for-performance (P4P) program in Taiwan did not reduce hospital admissions for severe hepatitis B or C patients needing antiviral therapy. Further research is needed to understand how P4P can improve patient-centered care.

Area of Science:

  • Hepatology
  • Health Services Research
  • Public Health

Background:

  • Investigating the impact of a participatory pay-for-performance (P4P) program in Taiwan.
  • Focusing on patients with severe hepatitis B or C.

Purpose of the Study:

  • To evaluate the effectiveness of a participatory P4P program on health outcomes.
  • Assessing the program's influence on hospital admissions and disease progression.

Main Methods:

  • Utilized 4-year panel data from Taiwan's National Health Insurance Administration (NHIA).
  • Employed caliper matching for one-to-one patient group comparison (2010-2013).
  • Applied Cox proportional-hazards regression models to analyze patient outcomes.

Main Results:

  • The P4P group did not show a statistically significant lower risk of hospital admission for severe hepatitis patients requiring antiviral therapy (HR = 0.44, P = 0.05).
  • A reduced risk of developing liver cirrhosis was observed in the P4P group, but this finding was not statistically significant (HR = 0.92, P = 0.77).

Conclusions:

  • Participatory P4P did not lead to decreased hospital admissions for hepatitis patients needing antiviral therapy.
  • The study discusses potential mechanisms for participatory P4P to enhance patient-centered care and improve health outcomes.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
295
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
250
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
645
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
404